Navy Preventive Medicine Teams Embark Ships in 7th Fleet

22 March 2020

From U.S. 7th Fleet Public Affairs

Members of Navy Forward-Deployed Preventive Medicine Units (FDPMU) and Naval Medical Research Center (NMRC) embarked several 7th Fleet ships March 14 to help combat the risk of and provide laboratory batch testing for COVID-19 onboard the ships.

Members of Navy Forward-Deployed Preventive Medicine Units
(FDPMU) and Naval Medical Research Center (NMRC) embarked several 7th Fleet
ships March 14 to help combat the risk of and provide laboratory batch
testing for COVID-19 onboard the ships.

Teams are embarked on the amphibious assault ship USS America (LHA 6), the
aircraft carrier USS Theodore Roosevelt (CVN 71), and the U.S. 7th Fleet
flagship USS Blue Ridge (LCC 19) and have the ability to batch test Sailors
onboard who present with influenza-like illness symptoms, instead of only
sending samples to be tested ashore.

This capability provides early-warning surveillance for the medical teams to
be able to identify if a COVID-19 case is onboard a ship, but does not
individually diagnose Sailors. If a batch were to test positive for
COVID-19, the medical teams would take additional measures, such as
isolating the Sailors whose samples were in the batch, and depending on the
Sailor's symptoms, potentially medically evacuating them off the ship to a
shore facility for testing.

To date, no cases of COVID-19 have been diagnosed aboard any U.S. 7th Fleet
Navy vessel.

"The team here in 7th Fleet has taken COVID-19 seriously from the beginning
and has many public health measures already in place," said Capt. Christine
Sears, U.S. 7th Fleet Surgeon. "The FDPMU and NMRC augmentation teams
provide additional depth in our ability to combat this virus."

Teams embarked the ships to provide at-sea testing and to ensure the U.S.
7th Fleet operating forces are ready to combat a possible outbreak while
maintaining mission readiness. The teams provide additional capabilities in
addition to the U.S. 7th Fleet's isolation procedures.

The teams are comprised of a variety of specialized Navy Medicine personnel
to ensure force health protection of the fleet, and may include: a
microbiologist, medical laboratory technician, preventive medicine officer,
preventive medicine technician.

"As a medical service corps microbiology officer, this embark gives us the
chance to demonstrate some of our skillsets to the fleet, and what we bring
to the fight," said Lt. Cmdr. Rebecca Pavlicek, Blue Ridge COVID-19 testing
team lead. "This capability allows us, the Navy, to protect mission
readiness and protection of our Sailors."

To ensure force health protection of the fleet, other medical specialties
or logistical components can be scaled up or down to meet mission specific
requirements in the mitigation, health surveillance, and casualty
prevention.

The 4-person team aboard America was the first to bring COVID-19 testing
capability to a U.S. Navy ship.

"This is the most advanced laboratory capability that Navy Medicine has
placed forward deployed," said Cmdr. Brian Legendre, team lead and
preventative medicine officer for the preventative medicine team aboard
America.

"We can make force health protection decisions in real time, enhancing the
health of the crew while minimizing any potential outbreak of COVID-19,"
added Lt. Cmdr. Danett Bishop, team microbiologist.

The FDPMU teams aboard the USS America and the USS Blue Ridge are from Navy
Environmental Preventative Medicine Unit Six based out of Pearl Harbor,
Hawaii, and work to facilitate and educate using preventive medicine
practices and provide additional laboratory capabilities. The team embarked
with USS Theodore Roosevelt is assigned to the Naval Medical Research Center
based in Silver Spring, Maryland.

Currently, the teams are only authorized to perform surveillance testing and
not individual testing. This means that the results cannot be linked to a
particular patient for diagnostics, but would enable the team to detect
COVID-19's presence on the ship based off of the results.

"Since we are performing surveillance testing, the results of COVID-19
present, or not present can help inform the force health protection posture
and provide valuable insight for the senior medical officer and outbreak
response team," said Pavlicek.

The teams are equipped with two testing capabilities, including the BioFire
Film Array and the Step One RT-PCR System. The BioFire Film Array will test
for a dozen different respiratory diseases, while the Step One RT-PCR System
allow for complex COVID-19 tests at sea, if necessary.

As the U.S. Navy's largest forward-deployed fleet, 7th Fleet operates
roughly 50-70 ships and submarines and 140 aircraft with approximately
20,000 Sailors.

Get more information about the Navy from US Navy facebook or twitter.

For more news from Commander, U.S. 7th Fleet, visit www.c7f.navy.mil/.

Guidance-Card-Icon Dept-Exclusive-Card-Icon